证券代码：000710 证券简称：贝瑞基因 公告编号：2025-017 成都市贝瑞和康基因技术股份有限公司 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议基本情况 1、会议届次：2024年年度股东大会 2、召集人：公司董事会 召开本次股东大会的议案经公司第十届董事会第十三次会议审议通过。 3、会议召开的合法、合规性：本次股东大会召开符合有关法律、行政法规、部 门规章、规范性文件、深圳证券交易所业务规则和公司章程等的规定。 4、会议时间： 现场会议召开时间：2025年5月20日（星期二）下午14:30 网络投票时间： 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5月20 日9:15—9:25、9:30—11:30、13:00—15:00；通过深圳证券交易所互联网投票系统 投票的具体时间为：2025年5月20日9:15—15:00。 5、会议召开方式： 本次股东大会采用现场表决与网络投票相结合的方式。本公司将通过深圳证券交 易所交易系统和互联网投票系统（http://wltp.cninfo ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.08 billion, a decrease of 6.36% compared to ¥1.15 billion in 2023[19]. - The net profit attributable to shareholders for 2024 was a loss of approximately ¥192.43 million, an improvement of 54.96% from a loss of ¥427.20 million in 2023[19]. - The net cash flow from operating activities for 2024 was approximately ¥87.97 million, down 20.75% from ¥111.01 million in 2023[19]. - The total assets at the end of 2024 were approximately ¥2.38 billion, a decrease of 13.00% from ¥2.74 billion at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥1.68 billion, down 9.90% from ¥1.86 billion at the end of 2023[19]. - The basic earnings per share for 2024 was -¥0.5443, an improvement of 54.96% from -¥1.2084 in 2023[19]. - The weighted average return on net assets for 2024 was -10.87%, an improvement of 9.64% from -20.51% in 2023[19]. - The company reported a decrease in revenue after deductions, with the adjusted operating revenue for 2024 being approximately ¥1.06 billion compared to ¥1.13 billion in 2023[20]. - The company's total revenue for the first quarter was approximately ¥279.48 million, with a decline to ¥255.50 million in the fourth quarter, representing a decrease of about 8.57%[24]. - The net profit attributable to shareholders was ¥8.24 million in the first quarter, but turned negative in the fourth quarter with a loss of ¥202.81 million[24]. - The net cash flow from operating activities showed significant fluctuations, with a negative cash flow of ¥42.72 million in the first quarter, turning positive to ¥65.07 million in the fourth quarter[24]. Market and Industry Insights - The global gene sequencing market was valued at approximately $15.7 billion in 2021, with expectations to grow to $37.7 billion by 2026, indicating a strong growth trajectory[32]. - The Chinese gene sequencing market is projected to grow from $1.59 billion in 2021 to $4.24 billion by 2026, capturing about 10.13% of the global market[32]. - The government has implemented several policies to promote prenatal diagnosis, which is expected to accelerate the adoption of genetic testing technologies in grassroots medical institutions[31]. Technology and Services - The company focuses on high-throughput sequencing technology and HiFi sequencing technology for genetic testing services, targeting reproductive health and genetic disease detection[33]. - The company aims to leverage advanced sequencing technology combined with artificial intelligence for clinical applications, enhancing service offerings to hospitals and medical laboratories[33]. - The company provides genetic testing services covering over 1,700 single-gene diseases, utilizing innovative third-generation HiFi sequencing technology[34]. - The "Beibian" non-invasive prenatal testing (NIPT) screens for three types of fetal chromosomal aneuploidy (T13, T18, T21) and includes 17 types of chromosomal abnormalities[36]. - The "Beibian Plus" NIPT offers screening for over 100 chromosomal and genomic diseases, as well as large fragment microdeletion syndromes[36]. - The "Beiquan'an" prenatal whole exome sequencing (WES) is widely used for prenatal diagnosis and hereditary disease diagnosis in children and adults[37]. - The company has developed intelligent data interpretation and management services through its smart data center and AI application center[34]. - The company is committed to expanding its research sequencing technology and product services to meet diverse analytical needs and better serve research users[30]. Financial Management and Governance - The company has established an independent financial accounting system, enabling it to independently make financial decisions and maintain a clear separation from the controlling shareholder's finances[117]. - The company maintains a complete and independent business operation, with no competition or unfair related transactions with the controlling shareholder or its affiliates[114]. - The company has a clear separation of its financial operations from the controlling shareholder, with independent banking accounts and tax obligations[117]. - The company has implemented strict approval procedures for any operational funds transactions with related parties, ensuring transparency and compliance[111]. - The company has committed to regular assessments and adjustments of its management systems based on feedback and evaluations[150]. - The company has established a special team to enhance the collection of receivables and assess credit risks associated with customers[176]. Research and Development - The company is currently developing multiple new products based on sequencing platforms, aiming to enhance product performance and expand clinical applications[75]. - The company has ongoing projects for third-generation sequencing technology, with 13 detection products under development[75]. - R&D investment decreased by 12.24% to ¥113,550,557.11 in 2024, accounting for 10.53% of operating revenue[77]. - The number of R&D personnel increased by 9.29% to 200, representing 14.27% of the total workforce[76]. Employee and Management Structure - The total number of employees at the end of the reporting period is 1,402, with 1,397 from major subsidiaries and 5 from the parent company[140]. - The professional composition includes 568 production personnel, 368 sales personnel, 294 technical personnel, 36 financial personnel, and 136 administrative personnel[141]. - The company has established a comprehensive salary system that integrates performance management and salary incentives to align with business development[142]. - The training program includes various branches focusing on professional skills, general workplace skills, cultural promotion, and leadership development[143][144]. Compliance and Risk Management - The company has not reported any significant internal control deficiencies during the reporting period[153]. - The internal control audit report indicates that the company maintained effective financial reporting internal controls as of December 31, 2024[154]. - The company has implemented corrective measures to enhance governance structure and internal controls, resulting in improved operational transparency and compliance[180]. - The company is at risk of technological and product innovation lag, which could affect market share and profit margins[103]. - The company is managing increasing accounts receivable as its business scales, which poses a risk of bad debts[105]. Strategic Partnerships and Collaborations - The company has established strategic partnerships with leading global suppliers like Illumina and PacBio to stay updated on market changes and technology trends[54]. - The company is actively pursuing market expansion through strategic partnerships and investments in biotechnology and real estate sectors[96]. Future Outlook - The company aims to improve operational efficiency and reduce risks associated with land and asset development through strategic asset sales[96]. - The company has outlined plans for future growth, emphasizing the importance of maintaining a strong financial position and operational capabilities[96].

一、召开情况 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-022 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届监事会 第八次会议于 2025 年 4 月 23 日在北京市昌平区生命园路 4 号院 5 号楼 8 层会 议室以现场会议的方式召开，会议通知已于 2025 年 4 月 11 日以邮件形式发送给 各位监事，与会的各位监事均已知悉与所议事项相关的必要信息。本次监事会会 议应出席监事 3 名，实际出席会议监事 3 名，会议由监事会主席李翔东先生主 持，董事会秘书列席了会议。会议的召开和表决程序符合有关法律、行政法规、 部门规章、规范性文件和公司章程的规定。 二、审议情况 成都市贝瑞和康基因技术股份有限公司 第十届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 报告期内公司监事会严格按照《中华人民共和国公司法》《深圳证券交易所 上市公司自律监管指引第 1 号—主板上市公司规范运作》《公司章程》《监事会 议事规则》等有关法律、法规、规范性文件勤勉尽责地开展各项工作，全体监事 认真负责、勤勉尽职完成各项 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-023 成都市贝瑞和康基因技术股份有限公司 第十届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、召开情况 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）第十届董事会 第十三次会议于 2025 年 4 月 23 日在北京市昌平区生命园路 4 号院 5 号楼 8 层 会议室以现场与通讯会议相结合的方式召开，会议通知已于 2025 年 4 月 16 日以 邮件形式发送给各位董事，与会的各位董事均已知悉与所议事项相关的必要信息。 本次董事会会议应出席董事 7 名，实际出席会议董事 7 名，会议由董事长高扬先 生主持，董事会秘书列席了会议。会议的召开和表决程序符合有关法律、行政法 规、部门规章、规范性文件和公司章程的规定。 二、审议情况 1、审议通过《2024 年年度报告全文及摘要》 表决结果：7 票同意，0 票反对，0 票弃权。 本议案会前已经公司董事会审计委员会审议通过，并同意提交公司董事会审 议。 年度报告全文及摘要将同日刊登在巨潮资讯网（www.cninfo ...

贝瑞基因（000710）公告，2024年营业收入10.78亿元，同比下降6.36%。归属于上市公司股东的净亏损 1.92亿元，去年同期净亏损4.27亿元。基本每股收益-0.5443元/股。公司计划不派发现金红利，不送红 股，不以公积金转增股本。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-013 成都市贝瑞和康基因技术股份有限公司 2024年度利润分配的预案 一、2024年度利润分配预案 经上会会计师事务所（特殊普通合伙）审计，成都市贝瑞和康基因技术股份 有限公司（以下简称"公司"）2024年度合并报表实现归属于母公司股东的净利 润为-192,428,499.73元，母公司实现净利润为-54,274,897.70元，截至2024年 12月31日，母公司累计未分配利润为-354,297,787.52元，合并报表累计未分配 利润为64,542,377.86元。根据合并报表、母公司报表中可供分配利润孰低的原 则，2024年度实际可供分配的利润为0元。 公司拟定2024年度利润分配预案为：2024年度不派发现金红利，不送红股， 也不进行资本公积金转增股本。 项目 本年度 上年度 上上年度 现金分红总额（元） 0 0 0 回购注销总额（元） 0 44,511,181.27 0 归属于上市公司股东 的净利润（元） -192,428,499.73 ...

（000710）")成立于2010年，15年来，一直致力于基因检测技术向临床应用的全面转化，目前已经有超 2000家医疗机构使用贝瑞基因的基因测序整体解决方案。 近日，《证券日报》记者走进贝瑞基因，与公司董事长高扬共同探讨在AI赋能医疗行业的当下，基因 检测行业如何发展创新；在行业竞争格局日益激烈的情况下，公司如何破局突围。 持续发力人工智能 作为个性化医疗的重要基石，基因检测行业处于飞速发展阶段，政策支持、技术突破和市场需求等共同 推动行业规模持续扩大。 作为A股基因检测概念第一股，成都市贝瑞和康基因技术股份有限公司(以下简称"贝瑞基因 数据安全是人工智能落地应用绕不开的话题。医疗数据涉及个人隐私，如何在利用数据提升医疗服务的 同时，确保数据安全与患者隐私，是当前AI医疗发展面临的重要挑战之一。由此，如何对临床数据进 行高质量标注及算法调优能力，将成为企业的重要竞争力。 "公司在清洗内部积累的数据时，已经进行了整体的梳理工作以及非常有效的信息标注工作。"高扬说。 科学技术不断迭代革新，个性化医疗时代正在崛起。 人工智能技术迅猛发展，"AI+"成为当下市场热点。世界经济论坛发布的报告预计，2024年到2032 ...

最新一期业绩显示，2024年三季报，公司实现营业收入8.23亿元，同比-4.96%；净利润1038.55万元，同 比107.70%，销售毛利率50.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)21贝瑞基因-15.89-10.482.3944.79亿行业平均 43.4948.264.72101.42亿行业中值29.2629.262.3044.79亿1天益医疗-2674.15-2674.151.6819.89亿2硕世生 物-1783.03-1783.031.1236.84亿3诺唯赞-537.02-537.022.4697.17亿4澳华内镜-511.00256.294.0953.85亿5博 晖创新-342.22-210.703.7752.53亿6康泰医学-260.3130.542.6650.63亿7华大基因-194.94213.242.02198.10亿 8奥精医疗-109.68-109.681.4019.87亿9睿昂基因-70.97-70.971.2311.19亿10热景生物-62.69-62.693.45112.36 亿11华大智造-52.66-52.663.95315.51亿 来源：金融界 ...

证券代码：000710 证券简称：贝瑞基因 成都市贝瑞和康基因技术股份有限公司 投资者关系活动记录表 编号：2025-003 | 投资者关系活动 | □特定对象调研 □分析师会议 | | | --- | --- | --- | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | ☑其他 （电话交流会） | | | 参与单位名称 | 民生证券、中信建投、国盛证券、东北证券、国联民生证券、国 | | | | 泰海通证券、东方财富证券、华金证券、中信证券、中银国际、 | | | | 信达证券、德邦证券、湘财证券、上海证券、兴业证券、国信证 | | | | 券、华源证券、方正证券、华金证券、浙商证券、中邮证券、东 | | | | 吴证券、首创证券、中泰证券、长城基金、上海阜盈投资、青榕 | | | | 资产、观富(北京)资产、北京九州鑫汇投资基金、上海禧弘私募 | | | | 基金、耕霁(上海)投资、深圳中天汇富基金、申银万国、上海匀 | | | | 升投资、上海易正朗投资、上海益和源资产、上海健顺投资、珠 | | | | 海尚石投资、APC ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-012 成都市贝瑞和康基因技术股份有限公司 关于全资子公司与首都医科大学附属北京儿童医院 鉴于甲乙双方于2022年11月共同申报了由北京市科学技术委员会、中关村科技园区 管理委员会委托的"首都临床特色诊疗技术研究及转化应用"项目"新生儿功能性出生 缺陷的早筛早诊关键技术研究及产品研发"课题（课题号：Z221100007422017），并承 担项目成果转化的任务。双方为推动项目成果的临床转化和商业化应用，本着平等互 利、优势互补、协同发展的原则，经友好协商，达成合作框架协议。 签署《项目成果转化合作框架协议》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次签署的《项目成果转化合作框架协议》相关约定付诸实施和实施过程中均 存在变动的可能性，具体的实施内容和进度将根据双方后续工作进一步落实和推进，敬 请广大投资者注意投资风险。 2、本次签署的《项目成果转化合作框架协议》对公司本年度及后续年度经营业绩 的影响需视协议双方后续实施情况而定。 3、公司最近三年披露的框架协议的情况详 ...